Statements Of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities
Net loss	$ (68,757,589)	$ (9,238,427)	$ (32,031,175)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	919,136	1,300,188	1,462,238
Amortization of intangibles	299,833	299,833	299,833
Amortization of deferred finance costs and debt discounts	7,703,336	2,977,119	1,331,549
Share-based compensation	1,050,260	2,293,731	2,487,441
Non-cash royalty (income), net			(2,353,718)
Gain on debt conversion		(75,612)
Loss on asset disposal	36,103	12,444	86,278
Adjustment of warrants and convertible debt features	47,450,066	(8,189,895)	(3,416,383)
Interest due from issuance of stock	551,296	192,128
Changes in operating assets and liabilities:
Accounts receivable	4,013,279	(447,613)	2,811,531
Other receivables	51,827	19,534	28,495
Inventories	219,202	937,810	(594,576)
Prepaid expenses and other current assets	429,025	(760,474)	827,297
Other assets	(1,376)	7,773	(2,223)
Accounts payable	(44,349)	(2,053,493)	(3,186,001)
Accrued liabilities	1,717,571	(514,689)	(1,090,072)
Deferred revenue	(1,969,264)	1,125,079	1,775,856
Other liabilities		(3,094)	(5,648)
Net cash used in operating activities	(6,331,644)	(12,117,658)	(31,569,278)
Cash flows from investing activities
Purchase of equipment		(130,699)	(1,031,749)
Net cash used in investing activities		(130,699)	(1,031,749)
Cash flows from financing activities
Payments of term note	(4,000,000)	(4,000,000)	(2,000,000)
Proceeds from revolving line of credit	37,237,131	54,806,154	77,109,376
Payments of revolving line of credit	(44,490,148)	(62,842,934)	(72,818,866)
Proceeds from subordinated convertible debt, net of issuance costs		7,738,351
Proceeds from Healthcare Royalty Partners debt	2,546,328	2,500,000	14,317,397
Payments of Healthcare Royalty Partners debt	(263,192)	(1,252,647)
Payments of Biosense Debt			(5,540,373)
Proceeds from issuance of stock and warrants, net of issuance costs	21,298,937	9,122,232	239,593
Net cash provided by financing activities	12,329,056	6,071,156	11,307,127
Net increase (decrease) in cash and cash equivalents	5,997,412	(6,177,201)	(21,293,900)
Cash and cash equivalents at beginning of period	7,777,718	13,954,919	35,248,819
Cash and cash equivalents at end of period	13,775,130	7,777,718	13,954,919
Supplemental disclosures of cash flow information:
Interest Paid	$ 3,187,353	$ 3,258,900	$ 859,494